Agilent Technologies Inc. and MRM Proteomics Inc. announce the launch of MRM Proteomics' PeptiQuant MRM Assay Kits for quality control in quantitative plasma proteomic analyses based on multiple-reaction monitoring.
MRM Proteomics developed the kits to assist in the inter- and intra-laboratory quality control of MRM experiments in conjunction with stable isotope-labeled standards:
• The PeptiQuant LC-MS Platform Performance Kit tests the effectiveness of the LC-MS platform.
• The PeptiQuant Workflow Performance Kit evaluates the performance of an entire LC-MRM-MS analytical workflow in human plasma from denaturation through digestion to detection.
"Mass spectrometry is becoming increasingly important in biomedical and biological research, especially with the launch of large-scale initiatives such as the Human Proteome Project, which depends on mass spectrometry as one of the main technology platforms," said Andrew Munk, CEO of MRM Proteomics. "The mass spec and proteomics communities currently lack standardized protocols and reagents to ensure high-quality data that can be reproduced by laboratories across the world using different mass-spec technologies. Our PeptiQuant(tm) targeted proteomics Platform and Workflow performance kits will ensure that high-quality data can be reproduced."
"Application of QQQ mass spectrometry to protein quantitation is growing rapidly, and the adoption of this technique will be dependent on robust protocols that can be used in multiple laboratories," said Steven Fischer, director of omics applications for Agilent. "Agilent is pleased to be working with MRM Proteomics to address this need. PeptiQuant kits from MRM Proteomics, combined with Agilent's UHPLC-QQQ MS/MS platform, can be used to ensure high-quality protein quantification data is being produced in labs around the world."